Fulgent Genetics (FLGT)
(Delayed Data from NSDQ)
$19.84 USD
-0.15 (-0.75%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $19.84 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.84 USD
-0.15 (-0.75%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $19.84 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Zacks News
Fullgent Genetics (FLGT) Crossed Above the 50-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?
Best Momentum Stocks to Buy for December 8th
by Zacks Equity Research
ACLS, FLGT, GHLD, and BERY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 8, 2021.
Is Bio-Rad Laboratories (BIO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Bio-Rad Laboratories (BIO) and Fullgent Genetics (FLGT) have performed compared to their sector so far this year.
New Strong Buy Stocks for December 8th
by Zacks Equity Research
ACLS, BERY, CTRN, FLGT, and GMS have been added to the Zacks Rank #1 (Strong Buy) List on December 8, 2021
New Strong Buy Stocks for December 2nd
by Zacks Equity Research
GOLF, FLGT, GNK, CDEV, and ATCO have been added to the Zacks Rank #1 (Strong Buy) List on December 2nd.
Is Bio-Rad Laboratories (BIO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Bio-Rad Laboratories (BIO) and Fullgent Genetics (FLGT) have performed compared to their sector so far this year.
Surging Earnings Estimates Signal Upside for Fullgent Genetics (FLGT) Stock
by Zacks Equity Research
Fullgent Genetics (FLGT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Best Momentum Stocks to Buy for November 19th
by Zacks Equity Research
AOSL, FLGT, AMRC, and SAIA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 19, 2021.
New Strong Buy Stocks for November 19th
by Zacks Equity Research
AOSL, FLGT, LAZY, MATX, and SCHN have been added to the Zacks Rank #1 (Strong Buy) List on November 19, 2021.
Fullgent Genetics (FLGT) Crossed Above the 200-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?
New Strong Buy Stocks for November 11th
by Zacks Equity Research
BLDR, FLGT, MRBK, CC, and NMRK have been added to the Zacks Rank #1 (Strong Buy) List on November 11th.
Fullgent Genetics (FLGT) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Fullgent Genetics (FLGT) delivered earnings and revenue surprises of 202.31% and -13.69%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Fulgent Genetics (FLGT) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
The recent buyout of CSI Laboratories and strategic investments in early cancer screening are likely to have contributed to growth for Fulgent Genetics (FLGT).
Earnings Preview: Fullgent Genetics (FLGT) Q3 Earnings Expected to Decline
by Zacks Equity Research
Fullgent Genetics (FLGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Value Investors Buy Fullgent Genetics (FLGT) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Omnicell (OMCL) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is FULGENT GENETIC (FLGT) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
New Strong Sell Stocks for August 17th
by Zacks Equity Research
ACCD, CHRS, ELVT, FLGT, and GSHD have been added to the Zacks Rank #5 (Strong Sell) List on August 17, 2021.
FULGENT GENETIC (FLGT) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
FULGENT GENETIC (FLGT) delivered earnings and revenue surprises of -0.78% and -21.06%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
FULGENT GENETIC (FLGT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, FULGENT GENETIC (FLGT) closed at $110.87, marking a +0.33% move from the previous day.
What's in Store for Fulgent Genetics (FLGT) in Q2 Earnings?
by Zacks Equity Research
Fulgent Genetics' (FLGT) Q2 results are likely to reflect growth in areas like adult neurogenetics, hereditary cancer, hereditary cardiovascular genetics, reproductive health and sequencing as a service.
FULGENT GENETIC (FLGT) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
FULGENT GENETIC (FLGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FULGENT GENETIC (FLGT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, FULGENT GENETIC (FLGT) closed at $92.25, marking a +0.36% move from the previous day.
Should You Invest in the SPDR S&P Health Care Services ETF (XHS)?
by Zacks Equity Research
Sector ETF report for XHS
FULGENT GENETIC (FLGT) Stock Moves -0.13%: What You Should Know
by Zacks Equity Research
FULGENT GENETIC (FLGT) closed the most recent trading day at $85.94, moving -0.13% from the previous trading session.